Inventor
TAYLOR CLARKE B
US23 patents
⚠️ This page may combine multiple inventors who share the name “TAYLOR CLARKE B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LYCERA CORP
18 patentsUS9896441B2Feb 20, 2018
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP6 citations83
US9266839B2Feb 23, 2016
Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP8 citations83
US9221814B2Dec 29, 2015
Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
LYCERA CORP8 citations83
US9370507B2Jun 21, 2016
Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP8 citations82
US10442798B2Oct 15, 2019
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP2 citations72
US10364237B2Jul 30, 2019
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP2 citations72
US9707211B2Jul 18, 2017
Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP4 citations72
US9580388B2Feb 28, 2017
Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP4 citations72
US9580391B2Feb 28, 2017
Saturated acyl guanidine for inhibition of F1F0-ATPase
LYCERA CORP4 citations72
US10189777B2Jan 29, 2019
Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP2 citations71
US10532088B2Jan 14, 2020
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
LYCERA CORP2 citations68
US10085972B2Oct 2, 2018
Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP1 citations62
US10611740B2Apr 7, 2020
Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP1 citations61
US10421751B2Sep 24, 2019
Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
LYCERA CORP2 citations61
US10392350B2Aug 27, 2019
N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP0 citations51
US9932313B2Apr 3, 2018
Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP1 citations51
US9914706B2Mar 13, 2018
N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP1 citations51
US9920012B2Mar 20, 2018
Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
LYCERA CORP1 citations50